NEW YORK, May 18, 2026, 06:05 EDT
Sunshine Biopharma (Nasdaq) shares pointed higher in premarket Monday, bouncing after a selloff Friday. Traders looked at a new $6 million share-and-warrant registration and noted the latest quarterly loss.
Sunshine Biopharma shares traded at $0.70 premarket at 6:00 a.m. ET, up 147% from the last close of $0.28, Public.com data showed. StockAnalysis reported the stock ended Friday at $0.2841, down 39.46%, then changed hands near $0.7111 in early hours trading.
Pre-market moves ahead of the regular open can be volatile. The Nasdaq lists pre-market trading hours from 4:00 a.m. to 9:30 a.m. ET, before regular trading starts at 9:30 a.m. Liquidity can be weaker and price swings bigger outside the main session, Nasdaq warns.
Sunshine Biopharma is facing dilution risk as it considers selling new shares. In a preliminary prospectus from May 12, the company registered up to $6 million of common units and pre-funded units, each common unit including one share and two Series C warrants. These warrants let holders buy stock at a fixed price.
Deal is on a “best efforts” basis. The placement agent looks for buyers but isn’t buying the securities directly. According to the company, the warrant exercise price started at $1.03. The final offering price could come in below market. SEC
Sunshine Biopharma expects its outstanding common shares to go up to around 10.8 million after the offering, from about 5.0 million previously, assuming no more warrants get exercised. The company figures net proceeds will come to about $5 million and plans to use the cash for general corporate needs, including working capital.
The Fort Lauderdale, Florida-based company posted first-quarter sales of $8.1 million, down 9.1% from the same period last year. Net loss for the quarter reached $1.24 million, or 25 cents a share. Sales fell mainly after distribution agreements ended at the close of 2025, according to the company’s latest quarterly filing.
Sunshine Biopharma said it had $6.9 million in cash as of March 31, and burned around $2.1 million in operating cash for the quarter. The company said its current cash and pharma product sales are expected to fund the business for about 17 months. Sunshine Biopharma said it does not have any committed capital sources and may have to raise more money.
The company sells generic drugs through Nora Pharma in Canada. These are cheaper medicines made with the same active ingredients as branded drugs. In its filing, the company said Nora has 60 generic prescription products already on the Canadian market and 22 more in development. Of those, 12 could launch during the rest of 2026.
CEO Steve Slilaty said in the April results release the company is “committed to reaching profitability in the near future” and will “continue expanding our generic drug portfolio.”
Peer read-through is narrow here. Teva Pharmaceutical and Viatris both have big international generic-drug operations, while Sunshine Biopharma depends on Canadian revenue and trades more on financing risk, cash burn, and its thin public float than any broader sector move.
Premarket gains could fade if the market turns to the financing plans. The S-1 shows no minimum sale, and the latest quarterly report warns that more money might not come on good terms. With shares trading under $1, dilution risk and strain over the Nasdaq listing are clear.
